Atherogenic functions of the AT1 receptor are enhanced by BDKRB2 (25, 41), and atherosclerosis-related endothelial dysfunction can be prevented by inhibition of angiotensin II AT1 receptor stimulation with an inhibitor of the angiotensin II-generating ACE (42, 43). This evidence concerns the gene BDKRB2 and endothelial dysfunction.